Tropomyosin receptor kinase (TRK) inhibitors—such as larotrectinib, entrectinib, and repotrectinib—have demonstrated efficacy in extracranial malignancies harboring NTRK fusions, and their capacity to penetrate the blood–brain barrier makes them attractive candidates in gliomas. This evidence concerns the gene NTRK1 and central nervous system cancer.